FibroBiologics shares rise 10.23% premarket after completing Phase 1/2 trial site onboarding for CYWC628 diabetic foot ulcer therapy.

FibroBiologics surged 10.23% in premarket trading following the completion of site onboarding for its Phase 1/2 clinical trial of CYWC628, an allogeneic fibroblast spheroid therapy targeting refractory diabetic foot ulcers. The trial, a multicenter, open-label study evaluating safety, tolerability, and efficacy, marks a critical step in advancing the therapy toward potential commercialization. The interim analysis after six weeks of treatment and collaboration with Southern Star Research, a leading CRO in APAC, further bolster investor confidence in the trial’s execution and data quality. CEO Pete O’Heeron emphasized the milestone as foundational for demonstrating the therapy’s potential as a breakthrough in DFU treatment. Insider purchases by CSO Hamid Khoja, totaling 30,000 shares, added to the positive sentiment, reinforcing management’s conviction in the company’s pipeline.